domingo, 8 de novembro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· March 5, 2026

Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue?

View original at finance.yahoo.com
Merck (MRK) Up 1.7% Since Last Earnings Report: Can It Continue? A month has gone by since the last earnings report for Merck (MRK). Shares have added about 1.7% in that time frame, outperforming the S&P 500…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Keytruda growth was negatively impacted by approximately $200 million due to the unfavorable timing of wholesaler purchases in the United States in Q4 2025

    80% confidence
  • Adjusted earnings per share are expected to be between $5.00 and $5.15 in 2026

    80% confidence
  • Merck expects revenues to be in the range of $65.5-$67.0 billion in 2026, representing year-over-year growth of 1% to 3%

    80% confidence
  • The adjusted gross margin is expected to be around 82% in 2026

    80% confidence
  • In 2026, Merck expects to buy back shares worth $3 billion

    80% confidence
  • Merck has a Zacks Rank #4 (Sell). We expect a below average return from the stock in the next few months

    80% confidence
  • Roche Holding has a Zacks Rank #3 (Hold)

    80% confidence
  • Generic competition for Januvia/Janumet, Bridion and Dificid is expected to hurt revenues by approximately $2.5 billion in 2026

    80% confidence
  • A lower-than-expected infant immunization rate and high inventory levels in the market hurt Enflonsia sales in Q4 2025

    80% confidence
  • The estimate of $70 billion was $20 billion more than its previous estimate a year ago

    80% confidence
  • The estimate of $70 billion was more than double the peak consensus estimate for Keytruda revenues of $35 billion in 2028

    80% confidence
  • Merck expects over $70 billion of potential non-risk-adjusted commercial opportunity for the current pipeline by the mid-2030s

    80% confidence
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Q4 2026 Biotech Catalyst Season: Regulatory Deadlines and Data Readouts Against Cost Discipline and Slipping Timelines
From late October 2026 to January 2027, mid-cap biotechs cluster pivotal data presentations (ESMO, AHA, AASLD), FDA decision dates (ivonescimab BLA on 2026-11-14, lorundrostat on 2026-12-22) and Q3 earnings. Alongside these, several companies are managing capital: lowering R&D and SG&A guidance, pushing clinical milestones into 2027, authorizing a $400M buyback, and pursuing a delisting. Late-stage programs in oncology, hepatitis delta, hypertension and women's health look near commercial inflection, while cost cuts and delays point to uneven balance-sheet strength.
A nossa leitura dos dados ›
Sinais que acompanhamos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Padrões que observamos ›
Onde as fontes divergem
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,996
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,996 factos verificados com a fonte5,552 documentos-fonte arquivados
Consulte estes dados → isubstrate.com